Compare CCNEP & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNEP | ICUCW |
|---|---|---|
| Founded | 1865 | N/A |
| Country | | United States |
| Employees | 950 | 17 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2021 |
| Metric | CCNEP | ICUCW |
|---|---|---|
| Price | $24.94 | $0.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1K | ★ 111.2K |
| Earning Date | 04-17-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $217,361,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.57 | $0.01 |
| 52 Week High | $25.44 | $0.08 |
| Indicator | CCNEP | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 55.35 | 46.23 |
| Support Level | $24.88 | $0.01 |
| Resistance Level | $25.18 | $0.04 |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 96.09 | 42.16 |
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.